Kilitch Drugs (India) Ltd Q4 FY2024 Concall Summary

Source transcript PDF: https://assets.stockscans.in/docs/95712dc84he5l2o8q7qmyr58.pdf

Key Takeaways


Ethiopia: The Monopoly That Changes Everything

Mukund Mehta: "I am hoping that it will repeat every six to nine months or at least a year same thing, same order for a couple of years or more than that, because we are the only supplier of Cephalosporin in Ethiopia and there is no other thing."

Ethiopia Market Structure & Competitive Moat

Mukund Mehta: "There is no dearth of a sale in Ethiopia. You can say that it's a seller's market. Whatever you produce, there are buyers to take it."

Khopoli Greenfield Plant: The Next Leg


Financial Outlook & Capital Allocation

Mukund Mehta: "we are not in a mood to sell it off or something like that as of the day. So there is no question of value because nearby project is selling at INR9,000 or INR10,000 per square feet, you know. So there is a huge value."

Domestic Business & Client Base


Unanswered Questions & Watchpoints


Guidance & Commitments

CommitmentSpecificsTimeline
Ethiopia government order executionBegin production for the $9.13 mn tender; payment within 7 days of deliveryQ2 FY25 (next month)
Ethiopia facility utilizationReach ~60% capacity for the full fiscal yearFY25
Ethiopia order repeatSame order expected to repeatEvery 6-12 months for at least a couple of years
FY25 revenue growth25-30% YoY, with 60-65% export and 35-40% domestic mixFY25
FY25 EBITDA marginMaintain or improve within 18-22%FY25
INR 500 cr revenue targetAchieved via Ethiopia orders and Khopoli plantBy 2027
Margin at INR 500 cr revenue22-24%At INR 500 cr scale
Khopoli plant validationValidation completedMay 2025
Khopoli plant production startCommercial production begins~3 months after validation (H2 CY2025)
Bhiwandi land monetizationSolution expected; monetization possibleThis fiscal year or maximum by next year
Receivables risk reductionShift to advance business or own-product promotion to minimize debtorsOngoing from Q2 FY25

Key Metrics

MetricQ4 FY24
Total operating revenue (standalone)₹39.14 cr, vs ₹43.28 cr in Q4 FY23
Total operating revenue (consolidated)₹44.82 cr, vs ₹45.48 cr in Q4 FY23
EBITDA (standalone)₹6.11 cr, vs ₹8.12 cr in Q4 FY23
EBITDA (consolidated)₹7.55 cr, vs ₹7.23 cr in Q4 FY23
PAT (standalone)₹3.64 cr, vs ₹5.13 cr in Q4 FY23
PAT (consolidated)₹3.68 cr, vs ₹2.90 cr in Q4 FY23
FY24 total operating revenue (consolidated)₹154.37 cr, vs ₹139.60 cr in FY23
FY24 EBITDA (consolidated)₹28.63 cr, vs ₹20.48 cr in FY23
FY24 PAT (consolidated)₹13.58 cr, vs ₹8.28 cr in FY23
FY24 EBITDA margin~18%
FY25 revenue growth guidance25%–30% YoY
Revenue target of ₹500 cr timelineby 2027
Ethiopia government tender awarded$9.13 million
Ethiopia facility capacity utilization (historical)5%–7% YoY
Ethiopia facility target capacity utilization (FY25)~60%
Revenue mix (exports vs domestic)60% exports, 40% domestic for FY24
Pharmaceutical products revenue contribution90%–94% of total revenue
Khopoli plant capex~₹100 cr
Bhiwandi land parcel size18.67 acres total
Kilitch stake in Bhiwandi land parcel40%–45%